Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

NCT00936741 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT00936741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00936741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome
Lead sponsor
Corcept Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2009
Completion date
September 30, 2012
Enrollment
30 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cushing's syndrome